1. Home
  2. TRDA vs FTW Comparison

TRDA vs FTW Comparison

Compare TRDA & FTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.67

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

FTW

EQV Ventures Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.59

Market Cap

470.2M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
TRDA
FTW
Founded
2016
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
404.4M
470.2M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
TRDA
FTW
Price
$11.67
$10.59
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
200.0K
N/A
Earning Date
02-26-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$61,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
N/A
52 Week High
$14.27
N/A

Technical Indicators

Market Signals
Indicator
TRDA
FTW
Relative Strength Index (RSI) 64.79 N/A
Support Level $10.34 N/A
Resistance Level $11.49 N/A
Average True Range (ATR) 0.72 0.00
MACD 0.08 0.00
Stochastic Oscillator 83.51 0.00

Price Performance

Historical Comparison
TRDA
FTW

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares

EQV Ventures Acquisition Corp is a blank check company.

Share on Social Networks: